JEITO

JEITO will be strongly represented at #JefferiesHealthcare from November 17 to 20! Rafaèle Tordjman, Ksenija Pavletic Mehdi AINOUCHE, Pascal Touchon, Claudio Costa-Neto, Julien ELRIC and Daniel Wolle Ph.D. will be delighted to meet entrepreneurs, investors, and all those driving innovation across the biopharma ecosystem at the Global Healthcare Conference. Looking forward to connecting and exploring new opportunities. #JefferiesHealthcare #PrivateEquity #Innovation #LifeSciences #Biopharma

Private equity in Healthcare, and especially in biopharma, plays a decisive role in turning cutting-edge science into real treatments for patients During the conference "𝘗𝘳𝘪𝘷𝘢𝘵𝘦 𝘌𝘲𝘶𝘪𝘵𝘺 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘍𝘪𝘯𝘢𝘯𝘤𝘪𝘯𝘨 𝘰𝘧 𝘐𝘯𝘥𝘶𝘴𝘵𝘳𝘺, 𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯 𝘢𝘯𝘥 𝘋𝘦𝘧𝘦𝘯𝘴𝘦", hosted by the Finance Group of École Polytechnique’s Department of Economics, our Managing Partner Sabine Dandiguian shared JEITO's strong commitment to accelerating breakthrough therapeutic innovation for the benefit of patients. As Sabine Dandiguian highlighted, late-stage financing — those phases where a drug moves from the clinic to market launch require expertise and financing power — is crucial for Europe to build its own champions in biotech and health innovation. Success takes more than capital: it needs a united European ecosystem linking research, funding, production, and market access. That's where our strategic autonomy is built. At JEITO, we help strengthen the European biopharma ecosystem, not only through our capital, but through our team's collective expertise across every step of the drug value chain. That's what makes the difference for the companies we support. Many thanks to Benjamin Forestier for the invitation and to all the speakers Alexandre L., Sam Javaherian, Côme Arhanchiague, Philippe Tibi, Jean Schmitt, Jean Hubert Vial for such an insightful discussion. #PrivateEquity #Innovation #LifeSciences #Healthcare #Biopharma

𝗣𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝗻𝗲𝘄𝘀 𝗳𝗼𝗿 𝘄𝗼𝗺𝗲𝗻’𝘀 𝗵𝗲𝗮𝗹𝘁𝗵 ! ⤵️ Our portfolio company Noema Pharma has just announced positive topline results from a Phase 2a open-label study evaluating Cendifensine in menopausal women suffering from moderate-to-severe vasomotor symptoms (VMS). Millions of women worldwide experience intense menopausal symptoms such as hot flashes and night sweats, with limited non-hormonal treatment options available. The investigational therapy Cendifensine demonstrated a 92% reduction in the number of hot flashes, showing strong potential as a new non-hormonal approach for women facing debilitating symptoms. Moreover, Cendifensine demonstrated potential to benefit additional menopausal symptoms, such as mood, food cravings, and fatigue. 👏 Congratulations to the Noema team for this important milestone 👉 https://lnkd.in/dyyweEH3 #FasterForThePatient #Innovation #LifeSciences #Biopharma 

We are delighted to share that CDR-Life Inc. has entered into a new Global Licensing Agreement with Boehringer Ingelheim to advance CDR111, an antibody-based trispecific T-cell engager for auto-immune diseases 🤝 This new collaboration with Boehringer Ingelheim is a great recognition of CDR-Life's platform ability to design high quality biologics that could bring meaningful benefits to patients with high unmet medical needs, by stimulating the immune system in oncology and resetting it in auto immune diseases. Under the terms of the agreement, CDR-Life Inc.-Life is eligible to receive up to $570 million, including $48 million in upfront and near-term payments, plus tiered royalties on future sales. Congratulations to the entire CDR-Life team 👏 We wish both CDR-Life and Boehringer Ingelheim a fruitful collaboration ahead. Learn more: https://lnkd.in/eePuVDKd #FasterForThePatient #Innovation #LifeSciences #Biopharma

JEITO's Founder and CEO Rafaèle Tordjman was on BFM Business last week to discuss why we made a significant participation in the $213M Series D round of Odyssey Therapeutics. A few key reasons behind this investment ⤵️ 1️⃣ A potential meaningful patient-benefit for millions of patients suffering from autoimmune and inflammatory diseases, notably inflammatory bowel diseases 2️⃣ A strong interest from major pharmaceutical companies seeking therapeutic innovations that addresses large populations with still high unmet needs make a real difference for patients. 3️⃣ A strong positioning of Jeito in this significant (>$200M) and competitive series D that reflects our expertise in this high potential therapeutic area illustrated through our portfolio exit of Hi-Bio, acquired by Biogen for $1.8B. Watch the full interview here 👉 https://lnkd.in/e4nUjFCf  #FasterForThePatient #PrivateEquity #LifeSciences #Biopharma #AutoimmuneDisease

From ESMO - European Society for Medical Oncology Congress 2025 Late Breaking Oral session! Our portfolio company CatalYm GmbH presented very promising Phase 2 results for visugromab in bladder cancer, showing a substantial increase in anti-tumor activity in combination with a PD-1 inhibitor. Congratulations to CatalYm's team for this new hope for patients! 👏 #FasterForThePatient #ESMO2025 #oncology #innovation #biopharma

We are delighted to announce the promotion of Ksenija Pavletic to General Partner at JEITO.   With over 25 years of global experience in healthcare and investment leadership, Ksenija combines operational and strategic expertise across clinical-stage biopharmas, having held senior leadership positions in various regional and global business, sales, and marketing roles.   As part of JEITO’s founding team, Ksenija has made a great contribution to the firm’s development since its inception. From Chief Commercial Officer, to Partner and now General Partner, she will continue to strengthen Jeito’s collective expertise with the objective to expand its portfolio of innovative companies to deliver meaningful benefits for patients.   Congratulations, Ksenija! 👏   #PrivateEquity #Leadership #Appointment #Innovation #Lifesciences 

We are delighted to announce our significant participation in the oversubscribed $213M Series D financing of Odyssey Therapeutics, a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases.   For us, Odyssey is a gem 💎 combining:   ⮕ A strong science, innovative approach and solid pipeline to advance treatments for immune disorders such as Inflammatory Bowel Disease, that affect large patient populations with still significant unmet needs ⮕ A very experienced management team made of veteran drug hunters and developers, led by CEO Gary D. Glick PhD   We believe Odyssey is well-positioned to generate significant value for patients and society. Jeito will leverage its global network, deep expertise, and track record in immunology and inflammatory to support the company’s development.   Discover more about this investment 👉 https://lnkd.in/eYqQSMY6   #FasterForThePatient #PrivateEquity #LifeSciences #Biopharma #AutoimmuneDisease #Innovation

Since JEITO's inception, creating sustainable value for patients and society has been at the core of our vision and daily mission. This approach is strongly aligned with the objective of delivering sustainable performance Our 2024 Sustainability Report offers a clear view of our journey, with steady progress within our portfolio: more drug candidates, more indications, and more clinical trials. Check out our key KPIs below ⤵️ Going faster for patients is not just our motto — it's our commitment in action. Thank you to the JEITO team, our portfolio companies, and our partners for your trust and collective contribution in bringing transformative benefits to patients. #PrivateEquity #Sustainability #LifeSciences #Innovation #Biopharma

We are honored to be ranked by CB Insights as #1 in terms of the quality of our recent investments. This highlights our selective approach and steady search for highly promising clinical biopharma companies developing breakthrough healthcare innovations that can bring transformational benefits for patients. We are proud to support our talented portfolio companies that all address severe diseases with high unmet medical needs with the objective of generating the greatest impact for patients and society. #FasterForThePatient #privateequity #VC #innovation #lifesciences #biopharma